MDR-101-MLK (MERCURY) Study: Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

Multiple Locations

Overview

Currently, patients receiving a transplanted kidney are required to take life-long immunosuppressive medications to prevent rejection of the transplanted kidney. These medications carry substantial side effects. In addition, these medicines often do not completely control damage to the kidney from the recipients’ immune system, ultimately causing the kidney to fail.

This study is looking at a novel cell-based therapy to reprogram the recipients’ immune system to accept a transplanted kidney without the need for long term use of immunosuppression drugs.

The purpose of the current Phase 3 study is to demonstrate the efficacy and safety of MDR-101 for the induction of transplant immune tolerance in a prospective, randomized, multicenter clinical trial. MDR-101 is intended to induce mixed lymphohematopoietic chimerism and donor specific immune tolerance in order to preserve transplant kidney function, avert transplant kidney rejection, and eliminate the cumulative and serious side effects associated with immunosuppressive drugs.

Patients will receive either standard anti-rejection medications or a single dose of MDR-101 via IV infustion post-kidney transplant.

The investigational drug and study-related procedures will be provided at no cost. There may also be compensation available for study-related travel and expenses.

 

You may be eligible for this study if you:

  • Are between 18 to 70 years of age;
  • Have a living, related kidney donation scheduled or upcoming
  • Are HLA and ABO matched with donor

 

Exclusion criteria:

  • Currently taking immunosuppressive therapy
  • Donor with a history of type 1 or type 2 diabetes melliltus
  • Other eligibility criteria may apply

 

Find out if you might be eligible by contacting:

Lenuta Micsa, MD @ 646.239.9748 or lmicsa@medeortx.com

Mercury Medeor @ 646.239.9748 or mercury@medeortx.com

 

Locations:

UNITED STATES —

Arizona

 

California

  • University of California San Diego Moores Cancer Center
  • La Jolla, California, United States, 92037
  • Contact: Mita Shah, M.D.    858-657-8043    mshah@ucsd.edu  

 

  • Loma Linda University Medical Center
  • Loma Linda, California, United States, 92354
  • Contact: Michael De Vera, MD    909-558-3650    mdevera@llu.edu  
  • Contact: Diane Scavone    909-558-3670    dscavone@llu.edu

 

 

 

Colorado

 

Connecticut

 

District of Columbia

 

Florida

 

Illinois

  • Loyola University Medical Center
  • Maywood, Illinois, United States, 60153-3328
  • Contact: Sanjeev Akkina    708-216-6389    sanjeev.akkina@lumc.edu
  • Contact: Mary Rose Evans       mevans11@luc.edu

 

Massachusetts

 

Minnesota

 

New Jersey

 

New York

  • Upstate University Hospital
  • Syracuse, New York, United States, 13210
  • Contact: Mark Laftavi, M.D.    716-898-3394    mlaftavi@buffalo.edu
  • Contact: Iulia Movileanu    3154644766    movileai@upstate.edu 

 

Ohio

 

Pennsylvania

 

Texas

 

 

Utah

 

Virginia

 

Wisconsin

 

 

CANADA —

Quebec

  • CIUSSS de l’Est- de-l’Île-de-Montréal Installation Hopital Maisonneuve-Rosemont
  • Montréal, Quebec, Canada, H1T 2M4
  • Contact: Suzon Collette    51425223403489    suzoncollette@gmail.com
  • Contact: Lucie Boutin    5142523400    lboutin.hmr@ssss.gouv.qc.ca